|
|
|
|
| LEADER |
07101nmm a2200409 u 4500 |
| 001 |
EB000666921 |
| 003 |
EBX01000000000000000520003 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783642593833
|
| 100 |
1 |
|
|a Scharrer, I.
|e [editor]
|
| 245 |
0 |
0 |
|a 31st Hemophilia Symposium
|h Elektronische Ressource
|b Hamburg 2000
|c edited by I. Scharrer, W. Schramm
|
| 250 |
|
|
|a 1st ed. 2002
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 2002, 2002
|
| 300 |
|
|
|a XXX, 287 p
|b online resource
|
| 505 |
0 |
|
|a Outpatient Treatment with Radiosynoviorthesis in Hemophilic Arthropathy -- Requirements for Future Hemophilia Treatment from the Patients’ Point of View -- Vic. Poster: Hemorrhagic Diathesis -- Molecular Basis of von Willebrand Disease Type IIC Miami -- Hemorrhagic Diathesis through acquired Factor XIII Inhibitor -- Liver Transplantation in a Patient with severe von Willebrand Disease Type 3: Levels of von Willebrand Factor Following Transplantation -- Clincal Course and Laboratory Findings in a Patient with a New Mutation Causing Wiskott-Aldrich Syndrome -- Role of acquired and inherited Prothrombotic Risk Factors in Pediatric Cerebral Venous Thrombosis — Preliminary Results of a Multicenter Case-Control Study -- Analysis of the Fibrinogen Genes of 40 Patients with Suspicion of Dys-, Hypo- or Afibrinogenemia -- Vld. Poster: Thrombophilic Diathesis -- Hereditary Antithrombin Deficiency — Results of a Family Study --
|
| 505 |
0 |
|
|a Elevated Factor IX and Factor XI as Risk Factors for Venous Thrombosis and Stroke -- Thrombophilic Risk Parameters in Juvenile »Idiopathic« Stroke Patients -- Inquiry into the Significance of Constantly Raised FVIII Values as a Factor in Thrombophilia -- Do Statins Increase the Homocysteine Level? -- Alpha 2-Macroglobulin Level regulates the Anticoagulant Cofactor Activity of Protein S in Cord and Adult Plasma -- Combined Prothrombotic Defects and Contraceptives — Risk Factor for Deep Venous Thrombosis in Adolescence -- Role of 23 bp Insertion in Exon 3 of the Endothelial Cell Protein C Receptor Gene in Venous Thrombophilia
|
| 505 |
0 |
|
|a Recurrent Fatal Intracranial Hemorrhage (ICH) in Two Non-Identical Twins suffering from Hemophilia B (Factor IX Activity < 1%) -- Progression of Thrombosis under Low Molecular Weight Heparin without Heparin-Induced Thrombocytopenia in a young Man: a Case Report -- Cardiac Tamponade in a Patient with acquired Factor VIII Inhibitor and Chronic Renal Failure -- Endoscopic Cholecystectomy in a 55-year-old Patient with Heparin-Induced Thrombocytopenia Type II and Replacement of Mitral and Aortic Valve and Tricuspidal Valve Anular Plasty -- Vlb. Poster: Hemophilia -- Successful Orthopedic Operations in Hemophilic Adults with Inhibitors against Factor VIII -- Evaluation of Clinical Efficacy of rFVIIa in Pediatrics -- Risk Factors for Thrombosis in Hemophilia — an Analysis -- Status of Pain in Patients with severe Haemophilic Arthropathies -- Results of a 5-year Clinical Study with a B-domain Deleted FVIII Concentrate (rFVIII-SQ) --
|
| 505 |
0 |
|
|a Presentation of the Johann-Lukas-Schoenlein-Award -- I. Epidemiology -- HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 1999/2000 Survey) -- Hemophilia 2000 — the Annual Survey of the Austrian Hemophilia Centers -- II. Inhibitors in Hemophilia -- Changes in Epitope Specificity and in Distribution of FVIII Antibodies during Immune Tolerance Therapy (ITT) in Hemophilia A Patients with FVIII Antibodies — a Case Report -- Clinical Experience with the Modified Bonn-Malmö Protocol since 1996 -- Course of Inhibitors in mild Hemophilia A with and without Immune Tolerance Treatment -- III. Therapy and Monitoring of Bleeds in Acute- and Intensive Care Medicine -- Management of Bleeding in Surgery and Intensive Care -- IV.. Pediatric Hemostaseology -- Frequency and Profile of viral posttransfusional Infections in Patients from Hemophilia Center Timisoara --
|
| 505 |
0 |
|
|a Symptomatic Onset of severe Hemophilia A in Childhood is dependent on the Presence of Prothrombotic Risk Factors -- Differences between Neonates and Adults in Plasmin Inhibitory and Antifibrinolytic Action of Aprotinin -- Shorter PFA-100 Closure Times (CT) in Neonates than in Adults: Role of Red Cells, White Cells, Platelets, and von Willebrand Factor -- V. Free Lectures -- Efficacy and Safety of a High Purity Protein C Concentrate in the Management of Patients with severe Congenital Protein C Deficiency -- Respective Roles of Factors II, VII, IX, and X in the Procoagulant Activity of FEIBA -- Capillary Microscopic and Rheological Dimensions for the Diagnosis of von-Willebrand-Disease in Comparison with other Hemorrhagic Diatheses -- Evaluation of Denaturing High Performance Liquid Chromatography (DHPLC) in the Analysis of Hemophilia A -- Vla. Poster: Clinic and Casuistic -- Rheumatoid Arthritis in a Patient with Hemophilia Arthropathy — a Case Report --
|
| 653 |
|
|
|a Critical care medicine
|
| 653 |
|
|
|a Blood Transfusion Medicine
|
| 653 |
|
|
|a Hematology
|
| 653 |
|
|
|a Anesthesiology
|
| 653 |
|
|
|a Blood transfusion
|
| 653 |
|
|
|a Hematology
|
| 653 |
|
|
|a Intensive / Critical Care Medicine
|
| 653 |
|
|
|a Pediatrics
|
| 653 |
|
|
|a Anesthesiology
|
| 653 |
|
|
|a Pediatrics
|
| 700 |
1 |
|
|a Schramm, W.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-59383-3?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.15
|
| 520 |
|
|
|a Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have
|